Abstract
BackgroundNonbiologic Disease-modifying anti-rheumatic drugs (nbDMARDs) and anti-tumor necrosis factor (anti-TNFs) have been used in AS patients who do not respond adequately to non-steroidal anti-inflammatories (NSAIDs). However, concerns exist regarding the...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
